Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ApicHope Pharmaceutical Co., Ltd (300723.SZ)
CNY40.92
+0.21 (+0.52%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 27, Yunrun Building 510320
Guangzhou, CN
Guangzhou, CN
CEO
Hanxiong Li
Website
gdyph.com
IPO
2017-11-16
ISIN CNE1000035J7
Description
ApicHope Pharmaceutical Co., Ltd, along with its various subsidiary entities, operates primarily in the pharmaceutical sector, focusing on the research, development, production, and distribution of medicinal products. The company boasts an extensive portfolio of offerings that address diverse therapeutic needs, including solutions for infectious diseases, pediatric health, cardiovascular conditions, genitourinary disorders, respiratory ailments, liver and digestive problems, and dermatological complaints. Furthermore, they supply a range of anti-inflammatory and pain-relieving medications. This enterprise, established in 2002, maintains its primary operations in Guangzhou, China. It adopted its current name, ApicHope Pharmaceutical Co., Ltd, in December 2021, having previously been known as Yipinhong Pharmaceutical Co.,Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY40.92
+0.21 (+0.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
18M
Beta
0.68
Float Shares
158.14M
Free Float %
35.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.07% | +6.58% | +5.93% | +32.46% | -13.36% | +30.88% | -11.56% | +38.52% | +143.54% | +383.06% | +383.06% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
40.92
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.87
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-35.7% Q1'26: +2.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+37.5% ★ Q1'26: +941.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-25.2% Q1'26: +1.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-33.4% Q1'26: +157.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-11.2% Q1'26: +94.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-19.55× Q1'26: 0.83× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.43B
est: 1.64B (-12.9%)
|
1.64B
est: 1.59B (+2.7%)
|
1.68B
est: 1.79B (-6.6%)
|
2.20B
est: 2.13B (+3.2%)
|
2.28B
est: 2.33B (-2.1%)
|
2.50B
est: 2.15B (+16.4%)
|
1.45B
est: 1.59B (-8.7%)
|
932.27M
est: 1.65B (-43.5%)
|
1.93B
1.93B – 1.93B
+17.3% YoY
|
2.28B
2.28B – 2.28B
+17.7% YoY
|
| EBITDA |
252.91M
est: 167.10M (+51.4%)
|
202.32M
est: 162.32M (+24.6%)
|
225.05M
est: 182.75M (+23.1%)
|
305.79M
est: 216.95M (+41.0%)
|
366.46M
est: 237.06M (+54.6%)
|
387.34M
est: 116.59M (+232.2%)
|
-115.53M
est: 86.16M (-234.1%)
|
-96.68M
est: 89.41M (-208.1%)
|
104.87M
104.87M – 104.87M
+17.3% YoY
|
123.41M
123.41M – 123.41M
+17.7% YoY
|
| EBIT |
216.86M
est: 80.42M (+169.7%)
|
164.36M
est: 78.12M (+110.4%)
|
184.38M
est: 87.95M (+109.6%)
|
256.25M
est: 104.41M (+145.4%)
|
294.58M
est: 114.09M (+158.2%)
|
229.35M
est: -85.72M (+367.6%)
|
-293.44M
est: -63.34M (-363.2%)
|
-311.66M
est: -65.74M (-374.1%)
|
-77.10M
-77.10M – -77.10M
-17.3% YoY
|
-90.73M
-90.73M – -90.73M
-17.7% YoY
|
| Net Income |
208.22M
est: 225.84M (-7.8%)
|
143.69M
est: 286.07M (-49.8%)
|
225.61M
est: 240.90M (-6.3%)
|
306.92M
est: 346.30M (-11.4%)
|
290.68M
est: 324.21M (-10.3%)
|
184.61M
est: 26.86M (+587.2%)
|
-540.04M
est: -528.51M (-2.2%)
|
-337.79M
est: 207.79M (-262.6%)
|
289.10M
289.10M – 289.10M
+39.1% YoY
|
338.79M
338.79M – 338.79M
+17.2% YoY
|
| SGA |
693.08M
est: 992.72M (-30.2%)
|
929.55M
est: 964.28M (-3.6%)
|
1.01B
est: 1.09B (-6.7%)
|
1.44B
est: 1.29B (+11.9%)
|
1.46B
est: 1.41B (+3.4%)
|
1.40B
est: 1.21B (+16.3%)
|
819.38M
est: 892.36M (-8.2%)
|
361.44M
est: 926.06M (-61.0%)
|
1.09B
1.09B – 1.09B
+17.3% YoY
|
1.28B
1.28B – 1.28B
+17.7% YoY
|
| EPS |
0.48
est: 0.50 (-4.0%)
|
0.33
est: 0.63 (-47.4%)
|
0.52
est: 0.53 (-2.5%)
|
0.71
est: 0.77 (-7.4%)
|
0.69
est: 0.72 (-3.9%)
|
0.42
est: 0.06 (+606.2%)
|
-1.20
est: -1.17 (-2.6%)
|
-0.75
est: 0.46 (-263.0%)
|
0.64
0.64 – 0.64
+39.1% YoY
|
0.75
0.75 – 0.75
+17.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-264.15M
OE per share TTM
-0.59
Owner's Yield
-1.33%
Maintenance CapEx ratio
1.35%
Maint CapEx / Avg PPE
71.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 18 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P China ETF GXC | 0.01% | 37.1K | 0.59% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 769.6K | 0.06% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 24.7K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 55.8K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.75M | 0.06% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 100.9K | 0.39% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 99.6K | 0.29% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 97.9K | 0.28% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 31.9K | 0.10% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 2.96M | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-210.0K
Shares Outstanding
451.69M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dongling Yang | Deputy GM & Non-Independent Director | — | female |
| Hanxiong Li | Chairman of the Board of Directors & GM | — | male |
| Huixing Zhang | Accounting Supervisor & Chief Financial Officer | — | male |
| Mingyuan Zhang | Deputy GM & Secretary of Board | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300723.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
